The Federal Biomedical Agency (FMBA) of Russia has developed a prototype of an analog of Zolgensma, a drug for patients with spinal muscular atrophy (SMA) . This was announced during a meeting of the State Duma Committee on Science and Higher Education by Vsevolod Belousov, Director of the Federal State Budgetary Institution “Federal Center for Brain Research and Neurotechnologies” of the FMBA of Russia.
“Let’s put it this way: we have a prototype, actually, we have a drug, and now certain interdepartmental agreements are needed on how to launch the clinical trials. It will depend on how we position this drug,” Belousov was quoted as saying by TASS.
According to him, the drug is “practically a structural biosimilar” of Zolgensma.
“Of course, we are at the stage when we have not launched clinical trials yet,” Vsevolod Belousov said.
The Expert Council of the Circle of Kindness approved the procurement of the 100th dose of Zolgensma in October.